Table 3.
Mean bodyweight‐adjusted apparent plasma clearance
| Historic adult data | Apparent clearance (L/day) | 80% lower‐bound interval | 125% upper‐bound interval |
|---|---|---|---|
| Adult target (70 kg) a | 0.29 | 0.23 | 0.36 |
| PK/PD study of children aged 6–11 y | Apparent clearance (L/day) | Lower 90% CI | Upper 90% CI |
| Children (70 kg) b | 0.20 | 0.17 | 0.22 |
| Children (50 kg) c | 0.15 | 0.13 | 0.16 |
| Children (27 kg) d | 0.09 | 0.08 | 0.09 |
Abbreviations: CI, confidence interval; PD, pharmacodynamic; PK, pharmacokinetic; SC, subcutaneous.
a
Historic adult data from the MENSA trial for a 70 kg individual; data in children aged 6–11 y.
b
Typical adult bodyweight.
c
Mean bodyweight in the ≥40 kg group receiving 100 mg mepolizumab SC.
d
Mean bodyweight in the <40 kg group receiving 40 mg mepolizumab SC.